Search results for "induced-fit docking"

showing 5 items of 5 documents

In Silico Insights towards the Identification of NLRP3 Druggable Hot Spots

2019

NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) activation has been linked to several chronic pathologies, including atherosclerosis, type-II diabetes, fibrosis, rheumatoid arthritis, and Alzheimer’s disease. Therefore, NLRP3 represents an appealing target for the development of innovative therapeutic approaches. A few companies are currently working on the discovery of selective modulators of NLRP3 inflammasome. Unfortunately, limited structural data are available for this target. To date, MCC950 represents one of the most promising noncovalent NLRP3 inhibitors. Recently, a possible region for the binding of MCC950 to the NLRP3 protein was described but no details were …

0301 basic medicineInflammasomesComputer sciencehomology modelingMolecular ConformationDruggabilitymcc950Ligands01 natural sciencesPyrin domainlcsh:Chemistrynlrp3 modulationlcsh:QH301-705.5SpectroscopyMolecular Structureintegumentary systemCommunicationInflammasomeGeneral MedicineComputer Science ApplicationsMolecular Docking SimulationdockingProtein Bindingmedicine.drugIn silicoinduced-fit dockingComputational biologyMolecular Dynamics Simulation010402 general chemistryCatalysisInorganic ChemistryStructure-Activity Relationship03 medical and health sciencesNLR Family Pyrin Domain-Containing 3 Proteinnacht domainmedicineHumansHomology modelingPhysical and Theoretical ChemistryMolecular BiologyBinding SitesOrganic ChemistryHydrogen BondingBinding processmolecular dynamics0104 chemical sciences030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Docking (molecular)MutationNACHT domainwalker bInternational Journal of Molecular Sciences
researchProduct

Studio del ruolo delle mutazioni “gatekeeper” V654A e T670I di c-kit kinase nell’interazione con inibitori attraverso un approccio misto Dinamica Mol…

2012

La sovraespressione del proto-oncogene c-kit è stata riscontrata nelle cellule ematopoietiche, nel cancro a piccole cellule del polmone e nei tumori stromali gastrointestinali1-3. L’importanza clinica dell’espressione di c-kit nei tumori ha indirizzato la ricerca verso inibitori di questa tirosina chinasi. Imatinib (Gleevec®) (in figura) è stato il primo farmaco utilizzato in terapia, ma la comparsa di mutazioni su c-kit ha portato ad una riduzione dell’efficacia o a completa resistenza a questo trattamento. In alternativa, altri composti si sono mostrati attivi anche nei confronti dei mutanti come ad esempio Sunitinib (Sutent®)4, ma la necessità di nuovi e più efficaci inibitori contro i m…

CKIT MUTAZIONI INDUCED-FIT DOCKINGSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors

2012

Studies of the the three-dimensional quantitative structure–activity relationships for ninety-five c-kit tyrosine kinase inhibitors were performed. Based on a co-crystallized compound (1 T46), known inhibitors were aligned with c-kit by induced-fit docking, and multiple training/test set splitting was performed to validate the selected pharmacophore model. The best pharmacophore model consisted of five features: one hydrogen-bond donor and four aromatic rings. Reliable statistics were obtained (R 2 = 0.95, R pred 2  = 0.75), and the model was validated by using it to select c-kit inhibitors from a database; 82.1% of the hits it retrieved were active. Accordingly, our model can be reliably u…

Models MolecularQuantitative structure–activity relationshipChemistryStereochemistryOrganic ChemistryQuantitative Structure-Activity RelationshipC-kit . 3D-QSAR . Kohonen maps . Induced-fit dockingSettore CHIM/08 - Chimica FarmaceuticaCatalysisComputer Science ApplicationsInorganic ChemistryProto-Oncogene Proteins c-kitComputational Theory and MathematicsDocking (molecular)Drug DiscoveryPhysical and Theoretical ChemistryPharmacophoreReceptorTyrosine kinaseProtein Kinase Inhibitors
researchProduct

Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods

2021

The selective inhibition of immunoproteasome is a valuable strategy to treat autoimmune, inflammatory diseases, and hematologic malignancies. Recently, a new series of amide derivatives as non-covalent inhibitors of the β1i subunit with Ki values in the low/submicromolar ranges have been identified. Here, we investigated the binding mechanism of the most potent and selective inhibitor, N-benzyl-2-(2-oxopyridin-1(2H)-yl)propanamide (1), to elucidate the steps from the ligand entrance into the binding pocket to the ligand-induced conformational changes. We carried out a total of 400 ns of MD-binding analyses, followed by 200 ns of plain MD. The trajectories clustering allowed identifying thre…

Proteasome Endopeptidase ComplexStereochemistryPharmaceutical ScienceOrganic chemistryinduced-fit dockingMolecular Dynamics Simulation01 natural sciencesArticlemetadynamicsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundimmunoproteasomeQD241-441AmideDrug DiscoveryOrganosilicon CompoundsPhysical and Theoretical Chemistrynon-covalent inhibitor030304 developmental biology0303 health sciencesBinding Sites010405 organic chemistrymolecular dynamicnon-covalent inhibitorsMetadynamicsRational designDipeptidesLigand (biochemistry)PropanamideSettore CHIM/08 - Chimica Farmaceuticamolecular dynamics0104 chemical sciencesMolecular Docking SimulationchemistryChemistry (miscellaneous)Docking (molecular)MD bindingMolecular MedicinemetadynamicLead compoundOligopeptidesProteasome InhibitorsAcetamideProtein BindingMolecules
researchProduct

Study of the role of “gatekeeper” mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/dock…

2011

The over-expression of c-kit proto-oncogene has been reported in hematopoietic cells, small cell lung cancer, and gastrointestinal stromal tumors. The clinical importance of c-kit expression in tumors focused the research towards inhibitors of this tyrosine kinase. Imatinib (Gleevec®) was the first compound used in therapy, but mutations on c-kit led to reduced effectiveness or ineffectiveness of this treatment. Other compounds are likely to be effective against mutants, such as Sunitinib (Sutent®), but the need for new and most effective inhibitors against mutants is still critical. We report mixed Molecular Dynamics/Docking study with the aim to unveil the molecular mechanism involved in …

Stromal cellbusiness.industryKinaseSunitinibMutantImatinibc-kit “gatekeeper” mutants V654A and T670I induced-fit dockingGeneral MedicineHypothesisPharmacologySettore CHIM/08 - Chimica FarmaceuticaHaematopoiesisDocking (molecular)MedicinebusinessTyrosine kinasemedicine.drug
researchProduct